UK Is Ready To Begin Trials Of Inhaled Coronavirus Vaccine

Inhalation Of A Drug For COVID-19 Treatment Is Better Than Intra-Muscular Injection

Inhalation Of A Drug For COVID-19 Treatment Is Better Than Intra-Muscular Injection

The United Kingdom has allowed the beginning of human clinical trials of the newly developed inhaled coronavirus vaccine. According to the researchers, direct delivery of drug dosage would provide better and positive immunity responsive towards the lungs, which will result in faster treatment and recovery of the infected individual. There is two main coronavirus antidote in the developmental process, one of which is by Oxford University, which has been paused for the time being.

The other possibly working inhaled coronavirus vaccine, which is being developed by a research team from Imperial College, has already initiated human clinical testing since June. There are around one hundred and eighty candidates for the coronavirus vaccine across the world, but none of them has been able to successfully reach their target.

Administration of COVID-19 drug via inhalation

During the inhaled coronavirus vaccine human trials, around thirty individuals with optimum health levels were induced with the antidote in the form of mist or aerosol. The procedure of induction was similar to the way asthma drugs are administered with the use of a nebulizer machine along with a mouthpiece or face mask.

The injections to treat seasonal flu could now also be administered in the form of a nasal spray to provide direct contact of the drug with the lung tissue as compared to piercing the epidermal skin with a syringe that could also result in infection and other possible complications.

The coronavirus pandemic, which has affected almost every individual’s life this year across the globe, has the ability to primarily infect humans by entering the host body via the opening of the nose and mouth and affecting the inner cell lining of the lungs, throat, and nose. There are such specific surface tissues that are able to produce different immune reaction as compared with the rest of the human body’s mechanism.

Rapid reaction and efficacy of airborne drug administration

Due to this, the inhaled coronavirus vaccine will be able to directly target the airway protective tissue lining, which will provide an effective and timely reaction to the given drug as compared to an antidote that is administered via intra-muscular injection.

The lead researcher for the inhaled coronavirus vaccine by Imperial College, Professor Robin Shattock, stated that multiple teams of scientists and researching staff are working across the world to find a viable cure for the deadly coronavirus pandemic by doing human clinical trials and testing, as the deadly infection has killed numerous individuals globally.

The clinical trials that are being conducted will provide us with the required information regarding the generating of a possible strong immune response by the human body against COVID-19 after it has been administered with an inhaled coronavirus vaccine along with other forms of drug administration. Even though numerous trials are being conducted on a large scale worldwide, they are still less possibility that they would be able to conclude the localized immune response in the throat, nose, and airway, which are some of the main sites of attack of the deadly coronavirus infection.

It could also become a possibility that one of the testing team would be able to develop a successful working antidote for coronavirus, but due to their wrong and faulty delivery method inside the body, it could be termed as not working. But only by following through with these human clinical trials, the results could be seen and observed, along with further correction of the methods.

The aim for administrating of an inhaled coronavirus vaccine is to assess the wellbeing, efficacy, and safety of the patient as the drug will enter the individual in the form of airborne droplets, like the coronavirus infection way of entering the host body and boost the immune responsiveness of the patient, rather than injecting the drug in the blood which will take some time before it starts its working inside the body.

Read also Europe Is Learning To Live With The COVID-19